BRAF and central nervous system neoplasm: The SACHA French prospective observational study (2020 to 2022) assessed the off-label or compassionate use of targeted drugs and demonstrated that certain targeted drugs, such as BRAF or MEK inhibitors, are among the most frequently utilized, with pediatric CNS tumors being the main indication [71].